ADD **TCS**

Soft operating print; growth acceleration key for re-rating

Emkay — Your success is our success

Information Technology ▸ Result Update ▸ **July 10, 2026** | **CMP (Rs): 2,050 | TP (Rs): 2,600**

TCS posted a soft operating performance in 1Q. Revenue was flat qoq (0.4% CC), at $7.6bn. EBITM contracted by 130bps qoq to 24%, largely owing to rollout of wage hike. Deal wins were steady at $9.5bn (book-to-bill of 1.2x). AI Services revenue for 1Q stood at ~$650mn (~8.5% of revenue; up 13.6% qoq). Life Sciences and Manufacturing are expected to see a recovery in 2Q, with continued momentum in Technology & Services and BFSI, while Consumer demand is likely to improve as macroeconomic and geopolitical headwinds ease. Per the management, AI is expected to reshape roles rather than drive significant job reductions, with increasing focus on AI-native skills, prompt engineering, and model management (testing/training) capabilities. The mgmt highlighted weaker-than-expected demand in 1Q owing to geopolitical uncertainties and client program deferrals; however, it remains optimistic about a recovery in 2Q, supported by a sizable pent-up tech backlog awaiting execution. Valuation is undemanding; however, a re-rating would require a visible acceleration in revenue growth. We uphold our current view and await stronger growth triggers. We largely retain our earnings estimate, factoring in the 1Q performance; maintain ADD and TP of Rs2,600, at 16x Jun-28E EPS.

Results summary

Revenue was flat qoq (0.4% CC) at $7.6bn, largely in line with our estimate. EBITM contracted by ~130bps qoq to 24.0%, slightly below our estimate, resulting from wage hike (-170bps) and targeted investments offset by currency (40bps) and operational efficiency. Order book TCV stood at $9.5bn in 1Q. TCV for North America, BFSI, and the Consumer business was $4.7bn, $2.5bn, and $1.4bn, respectively. Headcount increased 1.6% qoq to 593,798. TCS announced an interim dividend of Rs12/share. What we like: steady performance, uptick in BFSI growth, healthy deal intake. What we do not like: weakness in 4 of the 8 domains, moderation in cash conversion (OCF/EBITDA: ~67%).

Growth led by Tech & Services and BFSI across verticals, and UK, India, and APAC by geography

Growth was led by Regional markets (4% CC qoq), Tech & Services (1.7%), BFSI (1.6%), and CME (0.3%), offset by the decline in Consumer Business (4.0%), Life Sciences and Healthcare (1.0%), ER&U (0.7%), and Manufacturing (0.5%). Among geographies, growth was led by the UK (0.3% CC), India (7.6%), and APAC (1.4%), while North America and Continental Europe declined 0.4% and 0.2%, respectively.

Deal wins steady, with constructs changing and faster execution

Deal TCV came in at $9.5bn, anchored by a net-new $800mn AI-led business transformation mega deal with SKF (sixth mega deal in the last five quarters). Deal activity is seeing a gradual shift toward AI-led transformation, with increasing adoption of outcome-based and transaction-based models, particularly in autonomous GBS. Mega deals are increasingly integrating AI-led optimization and transformation from the outset, accelerating execution timelines.

TCS: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	2,553,240	2,670,210	2,891,016	3,015,910	3,168,475
EBITDA	674,070	723,980	769,186	807,637	848,493
Adj. PAT	485,530	528,200	559,078	584,415	614,388
Adj. EPS (Rs)	134.2	146.0	154.5	161.5	169.8
EBITDA margin (%)	26.4	27.1	26.6	26.8	26.8
EBITDA growth (%)	6.4	7.4	6.2	5.0	5.1
Adj. EPS growth (%)	5.8	8.8	5.8	4.5	5.1
RoE (%)	51.2	51.2	49.7	49.1	49.0
RoIC (%)	100.3	91.5	84.5	84.8	85.5
P/E (x)	15.3	15.1	13.4	12.7	12.1
EV/EBITDA (x)	10.3	9.6	9.0	8.5	8.0
P/B (x)	7.7	6.8	6.4	6.1	5.8
FCFF yield (%)	6.8	7.3	7.6	8.2	8.6

Source: Company, Emkay Research

Target Price – 12M	Jun-27
Change in TP (%)	**-**
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	26.8

Stock Data	**TCS IN**
52-week High (Rs)	3,367
52-week Low (Rs)	1,976
Shares outstanding (mn)	3,618.1
Market-cap (Rs bn)	7,415
Market-cap (USD mn)	77,739
Net-debt, FY27E (Rs mn)	(510,798.1)
ADTV-3M (mn shares)	4.8
ADTV-3M (Rs mn)	11,987.8
ADTV-3M (USD mn)	125.7
Free float (%)	28.2
Nifty-50	23,962.8
INR/USD	95.4

Shareholding, Mar-26	
Promoters (%)	71.8
FPIs/MFs (%)	9.7/13.4

Price Performance

(%)	1M	3M	12M
Absolute	(4.7)	(20.8)	(38.5)
Rel. to Nifty	(7.6)	(21.5)	(34.7)

1-Year share price trend (Rs)



Dipeshkumar Mehta
dipeshkumar.mehta@emkayglobal.com
+91-22-66121253

Jimit Gandhi
jimit.gandhi@emkayglobal.com
+91-22-66121255

Shivang Bagla
shivang.bagla@emkayglobal.com
+91-22-66242491

Earnings call KTAs

- Clients continue to prioritize investments in AI, modernization, cybersecurity, sovereign cloud, platform rationalization, and vendor consolidation.
- TCS has expanded its AI ecosystem through strategic partnerships with Anthropic and Mistral.
- BFSI delivered broad-based growth across geographies, and the management is optimistic about sustained momentum.
- Tech and Services maintained healthy growth, which is expected to continue.
- Consumer Business remains under pressure due to geopolitical uncertainties, inflationary load, and lower discretionary spending, particularly across North American non-essential retail and airlines. Demand is expected to improve as macro conditions stabilize.
- Life Sciences declined during the quarter, though demand for AI transformation automation and compliance initiatives is intact. The management expects it to recover at the start of 2Q.
- Manufacturing remained soft, particularly due to auto, with client decision-making affected by tariff pressures, macro uncertainty, EV recalibration, and supply chain realignment. However, the overall outlook is positive, based on multiple net new deals signed in 1Q.
- The Energy, Resources, and Utilities segment saw a slight decline in the quarter, though the management is still positive on growth prospects, driven by AI infrastructure buildout, electrification, renewables, energy security, and critical-material mining.
- TCS is well positioned to capture demand and accelerate growth as client spending normalizes and AI adoption scales up.
- AI-driven productivity typically deliver 10-15% gains per engagement through automation and lower effort requirements.
- The company added ~14k freshers in 1Q, with an evolving focus on AI-native skills.

Exhibit 1: TCS – Quarterly snapshot

Particular (Rs mn)	1QFY27	4QFY26	qoq (%)	1QFY26	yoy (%)
Net sales ($ mn)	7,624	7,621	0.0	7,421	2.7
Net sales	722,750	706,980	2.2	634,370	13.9
Operating expenses	537,190	514,220		465,620	
EBITDA	185,560	192,760	-3.7	168,750	10.0
- Margin (%)	25.7	27.3	-160.0	26.6	-90.0
Depreciation	12,390	14,060		13,610	
EBIT	173,170	178,700	-3.1	155,140	11.6
- Margin (%)	24.0	25.3	-130.0	24.5	-50.0
Other income (net)	12,950	4,920		14,650	
Exceptional items	-5,000	0		0	
Share of profit/(loss) of an associate	0	0		0	
PBT	181,120	183,620	-1.4	169,790	6.7
Tax provided	46,920	45,780		41,600	
PAT	134,200	137,840	-2.6	128,190	4.7
Non-controlling interest	710	660		590	
Reported net profit	133,490	137,180	-2.7	127,600	4.6
Emkay net profit	138,490	137,180	1.0	127,600	8.5
Reported EPS (Rs)	36.9	37.9	-2.7	35.3	4.6

Source: Company, Emkay Research

Exhibit 2: Actuals vs Estimates

(Rs mn)	Actual	Estimate		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Revenue ($ mn)	7,624	7,636	7,613	-0.2%	0.1%	Revenue was broadly in line with estimates.
Sales	722,750	723,916	720,486	-0.2%	0.3%	
EBIT	173,170	176,635	173,637	-2.0%	-0.3%	
EBIT margin	24.0%	24.4%	24.1%	-40 bps	-10 bps	EBITM was slightly below our expectations.
PAT	133,490	131,797	134,010	1.3%	-0.4%	Reported net profit beat estimates due to higher other income.

Source: Company, Emkay Research

Exhibit 3: Changes in estimates

(Rs mn)	FY27E			FY28E			FY29E		
	Old	New	Change	Old	New	Change	Old	New	Change
Revenue	30,905	30,856	-0.2%	32,136	32,084	-0.2%	33,406	33,352	-0.2%
yoy growth (%)	3.0	2.8		4.0	4.0		4.0	4.0	
Revenue	2,887,951	2,891,016	0.1%	3,020,753	3,015,910	-0.2%	3,173,563	3,168,475	-0.2%
EBIT	721,272	718,851	-0.3%	756,071	754,859	-0.2%	794,318	793,044	-0.2%
EBIT margins (%)	25.0	24.9		25.0	25.0		25.0	25.0	
Net profit	552,937	554,078	0.2%	585,355	584,415	-0.2%	615,387	614,388	-0.2%
EPS (Rs)	152.8	153.1	0.2%	161.8	161.5	-0.2%	170.1	169.8	-0.2%

Source: Company, Emkay Research

Exhibit 4: TCS – One-year forward PER



Source: Company, Emkay Research

Exhibit 5: TCS – Key operating metrics

Metric	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	$ mn	qoq chg	yoy chg
Revenue ($ mn)	7,505	7,670	7,539	7,465	7,421	7,466	7,509	7,621	7,624		0.0%	2.7%
Revenue by geography (%)												
North America	49.5	47.6	47.7	48.2	48.7	48.8	48.5	48.5	48.3	3,682.4	-0.4%	1.9%
Latin America	1.9	1.8	1.9	1.8	1.9	1.9	2.0	1.9	2.0	152.5	5.3%	8.1%
UK	16.9	17.0	16.6	16.8	18.0	17.5	16.9	17.2	17.2	1,311.3	0.0%	-1.8%
Continental Europe	14.4	14.6	13.9	14.3	15.0	15.3	15.6	15.6	15.4	1,174.1	-1.2%	5.5%
India	7.5	8.9	9.8	8.4	5.8	5.8	6.1	6.0	6.2	472.7	3.4%	9.8%
Asia Pacific	7.8	8.0	7.8	8.1	8.4	8.3	8.3	8.3	8.4	640.4	1.2%	2.7%
MEA	2.0	2.1	2.3	2.4	2.2	2.4	2.6	2.5	2.5	190.6	0.0%	16.7%
CC revenue growth yoy by geography (%)												
North America	(1.1)	(2.1)	(2.3)	(1.9)	(2.7)	(0.1)	1.3	2.5	2.0			
Latin America	6.3	6.8	7.0	4.3	3.5	1.8	1.4	(2.9)	(2.1)			
UK	6.0	4.6	4.1	1.2	(1.3)	(1.9)	(3.2)	(1.2)	(0.6)			
Continental Europe	0.9	1.8	(1.5)	1.4	(3.1)	(3.0)	1.4	1.0	4.3			
India	61.8	95.2	70.2	33.0	(21.7)	(33.3)	(34.3)	(23.0)	22.9			
Asia Pacific	7.6	7.5	5.8	6.4	3.6	2.0	3.5	0.4	2.5			
MEA	8.5	7.9	15.0	13.2	9.4	12.7	8.3	7.8	7.6			
Revenue by vertical (%)												
BFSI	30.9	30.8	30.5	31.2	32.0	32.2	31.9	31.6	32.1	2,447	1.6%	3.1%
Consumer Business	15.4	15.1	15.3	15.3	15.6	15.3	15.4	15.7	15.0	1,144	-4.4%	-1.2%
Communication & Media	6.2	5.9	5.8	5.8	5.8	5.9	5.9	5.8	5.8	442	0.0%	2.7%
Manufacturing	8.8	8.6	8.4	8.4	8.7	8.8	8.8	8.8	8.7	663	-1.1%	2.7%
Life Sciences & Healthcare	11.0	10.4	10.1	10.1	10.2	10.5	10.5	10.4	10.3	785	-0.9%	3.7%
Technology & Services	8.1	8.0	8.0	8.1	8.4	8.5	8.4	8.4	8.5	648	1.2%	4.0%
Regional Markets & Others	14.0	15.5	16.3	15.4	13.4	12.9	13.1	13.0	13.3	1,014	2.3%	2.0%
Energy, Resources and Utilities	5.6	5.7	5.6	5.7	5.9	5.9	6.0	6.3	6.3	480	0.0%	9.7%
CC revenue growth yoy by vertical (%)												
BFSI	(0.9)	0.1	0.9	2.5	1.0	1.0	1.6	0.4	2.4			
Consumer Business	(0.3)	0.1	1.1	(0.2)	(3.1)	(2.9)	(2.7)	0.8	(1.2)			
Life Sciences & Healthcare	4.0	0.1	(4.3)	(5.6)	(9.6)	(2.2)	2.2	3.3	3.5			
Technology & Services	(3.9)	(1.9)	(0.4)	1.1	1.8	2.8	1.7	2.5	3.5			
Manufacturing	9.4	5.3	0.4	(2.9)	(4.0)	(1.1)	1.7	3.1	2.9			
Communication & Media	(7.4)	(10.3)	(10.6)	(9.8)	(9.6)	(5.1)	(1.6)	(2.1)	1.4			
Energy, Resources and Utilities	5.7	7.0	3.4	4.6	2.8	0.2	2.2	7.3	6.9			
Regional Markets & Others	37.7	50.4	40.9	22.5	(8.6)	(18.1)	(19.4)	(12.8)	9.0			
Deal wins ($ bn)												
Deal win TCV	8.3	8.6	10.2	12.2	9.4	10.0	9.3	12.0	9.5		-20.8%	1.1%
- BFSI	2.7	2.9	3.2	4.0	2.5	3.2	3.8	3.9	2.5		-35.9%	0.0%
- Retail & CPG	1.1	1.2	1.3	1.7	1.6	1.8	1.4	2.8	1.4		-50.0%	-12.5%
- North America	4.6	4.2	5.9	6.8	4.4	4.3	4.9	5.4	4.7		-13.0%	6.8%
Book-to-bill (x)	1.11	1.12	1.35	1.63	1.27	1.34	1.24	1.57	1.25			
TTM book-to-bill (x)	1.39	1.28	0.78	0.76	1.34	1.40	1.37	1.36	1.35			
TTM deal win TCV	40.8	38.2	40.3	39.3	40.4	41.8	40.9	40.7	40.8		0.2%	1.0%
AI metrics												
AI services revenue ($ mn)						375.0	450.0	575.0	650.0		13.0%	
AI services revenue (% of revenue)						5.0	6.0	7.5	8.5			
Non-AI revenue ($ mn)						7,091.0	7,059.0	7,046.0	6,974.0		-1.0%	
Clients' contribution (no of; basis LTM revenue)												
>$1mn clients	1,310	1,307	1,309	1,332	1,336	1,360	1,383	1,397	1,401		4	65
>$5mn clients	697	710	722	723	714	707	721	738	746		8	32
>$10mn clients	486	491	497	493	495	498	497	499	504		5	9
>$20mn clients	300	298	294	298	300	302	310	311	307		(4)	7
>$50mn clients	140	136	134	130	131	136	136	139	139		-	8
>$100mn clients	63	66	64	64	62	60	62	66	66		-	4
Currency mix (%)												
USD	51.5	49.3	49.4	49.7	49.7	49.8	49.3	49.0	48.7	3,709.1	-0.6%	0.5%
GBP	14.6	14.9	14.4	14.7	15.8	15.2	14.8	15.1	15.1	1,151.2	-0.2%	-1.7%
Euro	11.0	11.2	10.6	11.0	11.7	11.7	11.7	11.9	11.9	905.7	0.2%	4.8%
Others	22.9	24.7	25.5	24.6	22.8	23.3	24.2	24.1	24.4	1,858.0	1.4%	9.6%
Avg INR rate												
USD	83.4	83.8	84.9	86.4	85.5	88.1	89.3	92.8	94.8		2.2%	10.9%
GBP	105.4	110.2	107.7	109.7	115.8	118.1	118.9	124.7	126.8		1.7%	9.5%
Euro	89.7	92.4	89.6	91.5	98.0	102.7	104.0	108.1	109.8		1.6%	12.0%
Employees (no of)												
Total employees (incl Indian subsidiaries)	606,998	612,724	607,354	607,979	613,069	593,314	582,163	584,519	593,798		1.6%	-3.1%
Net addition	5,452	5,726	(5,370)	625	5,090	(19,755)	(11,151)	2,356	9,279			
Attrition - IT services, LTM (%)	12.1	12.3	13.0	13.2	13.8	13.3	13.5	13.7	13.6			

Source: Company, Emkay Research

TCS: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	**2,553,240**	**2,670,210**	**2,891,016**	**3,015,910**	**3,168,475**
Revenue growth (%)	6.0	4.6	8.3	4.3	5.1
EBITDA	**674,070**	**723,980**	**769,186**	**807,637**	**848,493**
EBITDA growth (%)	6.4	7.4	6.2	5.0	5.1
Depreciation & Amortization	52,420	55,600	50,335	52,778	55,448
EBIT	**621,650**	**668,380**	**718,851**	**754,859**	**793,044**
EBIT growth (%)	6.5	7.5	7.6	5.0	5.1
Other operating income	-	-	-	-	-
Other income	39,620	44,020	44,429	43,189	45,635
Financial expense	7,960	8,850	9,930	9,600	9,600
PBT	**653,310**	**703,550**	**753,350**	**788,448**	**829,079**
Extraordinary items	0	(36,100)	(5,000)	0	0
Taxes	165,340	172,910	191,564	201,054	211,415
Minority interest	(2,440)	(2,440)	(2,708)	(2,979)	(3,277)
Income from JV/Associates	0	0	0	0	0
Reported PAT	**485,530**	**492,100**	**554,078**	**584,415**	**614,388**
PAT growth (%)	5.8	1.4	12.6	5.5	5.1
Adjusted PAT	**485,530**	**528,200**	**559,078**	**584,415**	**614,388**
Diluted EPS (Rs)	**134.2**	**146.0**	**154.5**	**161.5**	**169.8**
Diluted EPS growth (%)	5.8	8.8	5.8	4.5	5.1
DPS (Rs)	**126.0**	**110.0**	**136.0**	**143.0**	**153.0**
Dividend payout (%)	**93.9**	**80.9**	**88.8**	**88.5**	**90.1**
EBITDA margin (%)	26.4	27.1	26.6	26.8	26.8
EBIT margin (%)	24.3	25.0	24.9	25.0	25.0
Effective tax rate (%)	25.3	24.6	25.4	25.5	25.5
NOPLAT (pre-IndAS)	**464,323**	**504,114**	**536,060**	**562,370**	**590,818**
Shares outstanding (mn)	3,618	3,618	3,618	3,618	3,618

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	3,620	3,620	3,620	3,620	3,620
Reserves & Surplus	965,200	1,090,140	1,152,158	1,219,187	1,280,007
Net worth	**968,820**	**1,093,760**	**1,155,778**	**1,222,807**	**1,283,627**
Minority interests	10,150	12,380	15,088	18,067	21,343
Non-current liab. & prov.	(25,600)	(32,220)	(32,220)	(32,220)	(32,220)
Total debt	**0**	**0**	**0**	**0**	**0**
Total liabilities & equity	**1,047,290**	**1,188,010**	**1,253,736**	**1,324,743**	**1,389,840**
Net tangible fixed assets	129,320	159,320	160,320	161,320	162,320
Net intangible assets	9,400	1,760	1,760	1,760	1,760
Net ROU assets	92,750	92,750	92,750	92,750	92,750
Capital WIP	-	-	-	-	-
Goodwill	-	-	-	-	-
Investments [JV/Associates]	-	-	-	-	-
Cash & equivalents	**472,300**	**476,210**	**510,798**	**556,140**	**590,329**
Current assets (ex-cash)	838,140	957,950	1,005,698	1,048,048	1,099,117
Current Liab. & Prov.	534,860	612,800	630,410	648,095	669,256
NWC (ex-cash)	**303,280**	**345,150**	**375,288**	**399,953**	**429,861**
Total assets	**1,047,290**	**1,188,010**	**1,253,736**	**1,324,743**	**1,389,840**
Net debt	(472,300)	(476,210)	(510,798)	(556,140)	(590,329)
Capital employed	1,047,290	1,188,010	1,253,736	1,324,743	1,389,840
Invested capital	**482,240**	**619,050**	**650,188**	**675,853**	**706,761**
BVPS (Rs)	267.8	302.3	319.4	338.0	354.8
Net Debt/Equity (x)	(0.5)	(0.4)	(0.4)	(0.5)	(0.5)
Net Debt/EBITDA (x)	(0.7)	(0.7)	(0.7)	(0.7)	(0.7)
Interest coverage (x)	83.1	80.5	76.9	83.1	87.4
RoCE (%)	**69.1**	**68.3**	**67.0**	**66.2**	**65.9**

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
PBT (ex-other income)	643,830	638,380	554,078	584,415	614,388
Others (non-cash items)	218,610	222,940	53,043	55,757	58,725
Taxes paid	(155,860)	(143,840)	0	0	0
Change in NWC	(36,460)	(27,260)	(30,138)	(24,665)	(29,908)
Operating cash flow	**514,260**	**546,380**	**576,983**	**615,507**	**643,205**
Capital expenditure	(39,090)	(40,900)	(51,335)	(53,778)	(56,448)
Acquisition of business	(10,630)	(73,040)	0	0	0
Interest & dividend income	33,430	39,010	32,959	35,989	38,435
Investing cash flow	**(56,760)**	**(162,900)**	**(54,995)**	**(53,778)**	**(56,448)**
Equity raised/(repaid)	0	2,000	0	0	0
Debt raised/(repaid)	0	0	0	0	0
Payment of lease liabilities	(16,640)	(18,610)	1,000	1,000	1,000
Interest paid	-	-	-	-	-
Dividend paid (incl tax)	(449,620)	(395,710)	(492,060)	(517,387)	(553,567)
Others	280	0	0	0	0
Financing cash flow	**(465,980)**	**(412,320)**	**(491,060)**	**(516,387)**	**(552,567)**
Net chg in Cash	(8,480)	(28,840)	30,928	45,342	34,189
OCF	514,260	546,380	576,983	615,507	643,205
Adj. OCF (w/o NWC chg.)	550,720	573,640	607,121	640,172	673,112
FCFF	475,170	505,480	525,648	561,729	586,756
FCFE	500,640	535,640	548,677	588,118	615,591
OCF/EBITDA (%)	76.3	75.5	75.0	76.2	75.8
FCFE/PAT (%)	103.1	108.8	99.0	100.6	100.2
FCFF/NOPLAT (%)	**102.3**	**100.3**	**98.1**	**99.9**	**99.3**

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	15.3	15.1	13.4	12.7	12.1
EV/CE(x)	7.1	6.3	5.9	5.5	5.2
P/B (x)	7.7	6.8	6.4	6.1	5.8
EV/Sales (x)	2.7	2.6	2.4	2.3	2.2
EV/EBITDA (x)	10.3	9.6	9.0	8.5	8.0
EV/EBIT(x)	11.2	10.4	9.6	9.1	8.6
EV/IC (x)	14.4	11.2	10.6	10.1	9.7
FCFF yield (%)	6.8	7.3	7.6	8.2	8.6
FCFE yield (%)	6.8	7.2	7.4	7.9	8.3
Dividend yield (%)	6.1	5.4	6.6	7.0	7.5
DuPont-RoE split					
Net profit margin (%)	19.0	19.8	19.3	19.4	19.4
Total asset turnover (x)	2.7	2.6	2.6	2.5	2.5
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	**51.2**	**51.2**	**49.7**	**49.1**	**49.0**
DuPont-RoIC					
NOPLAT margin (%)	18.2	18.9	18.5	18.6	18.6
IC turnover (x)	5.5	4.8	4.6	4.5	4.6
RoIC (%)	**100.3**	**91.5**	**84.5**	**84.8**	**85.5**
Operating metrics					
Core NWC days	43.4	47.2	47.4	48.4	49.5
Total NWC days	**43.4**	**47.2**	**47.4**	**48.4**	**49.5**
Fixed asset turnover	15.2	11.8	10.5	11.0	11.5
Opex-to-revenue (%)	73.6	72.9	73.4	73.2	73.2

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
01-Jul-26	1,983	2,600	Add	Dipeshkumar Mehta
10-Apr-26	2,524	2,950	Add	Dipeshkumar Mehta
31-Mar-26	2,359	2,800	Add	Dipeshkumar Mehta
05-Mar-26	2,579	2,800	Add	Dipeshkumar Mehta
18-Feb-26	2,695	3,500	Add	Dipeshkumar Mehta
13-Jan-26	3,268	3,500	Add	Dipeshkumar Mehta
01-Jan-26	3,227	3,500	Add	Dipeshkumar Mehta
18-Dec-25	3,281	3,250	Add	Dipeshkumar Mehta
11-Dec-25	3,192	3,250	Add	Dipeshkumar Mehta
21-Nov-25	3,151	3,250	Add	Dipeshkumar Mehta
01-Nov-25	3,058	3,250	Add	Dipeshkumar Mehta
10-Oct-25	3,028	3,250	Add	Dipeshkumar Mehta
01-Oct-25	2,914	3,250	Add	Dipeshkumar Mehta
11-Jul-25	3,266	3,500	Add	Dipeshkumar Mehta
01-Jul-25	3,430	3,500	Add	Dipeshkumar Mehta
11-Apr-25	3,232	3,500	Add	Dipeshkumar Mehta
31-Mar-25	3,606	3,900	Add	Dipeshkumar Mehta
10-Jan-25	4,266	4,500	Add	Dipeshkumar Mehta
01-Jan-25	4,112	4,500	Add	Dipeshkumar Mehta
11-Oct-24	4,149	4,500	Reduce	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

[1] An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

[2] Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 10, 2026
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 10, 2026
5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 10, 2026
6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.
CIN - L67120MH1995PLC084899
7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

Seshadri Kumar Sen

Digitally signed by Seshadri Kumar Sen
Date: 2026.07.10 01:27:35 +05'30'